Navigation Links
AMDL Announces Preliminary Third Quarter Earnings; Revises 2008 Guidance
Date:11/12/2008

TUSTIN, Calif., Nov. 12 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL), a vertically integrated pharmaceutical company with operations in China and the US, announced today preliminary third quarter earnings and revised 2008 guidance information.

For the third quarter of FY2008, AMDL expects gross sales to be approximately $12.4 million and net sales after sales promotions of approximately $9.2 million. Gross profit is expected to be approximately $4.9 million and income from operations to be approximately $2.3 million. The Company expected net income before currency translation to be approximately $1.6 million.

Earnings were originally projected to be approximately $3.4 million. However, the Company made a strategic decision to offer promotional discounts of $3.2 million to promote new product sales in the Chinese marketplace, primarily for the newly released formulations of AMDL's best-selling Goodnak(R) anti-aging product line. The existing promotional discounts will carry forward into the fourth quarter of 2008 and the first quarter of 2009. Based upon this information, AMDL continues to anticipate targeted gross sales of approximately $32 to $36 million for 2008. With regards to earnings guidance, the Company now estimates net income before foreign currency translation to be between $1.8 and $ 2.2 million for FY2008.

"We're operating AMDL for long-term success in a period of accelerated growth," said AMDL's Chairman and newly appointed CEO Mr. Douglas MacLellan. "We made a strategic and conscious decision to provide sales promotion discounts for certain new products in the third and fourth quarters which we believe will accelerate the introduction and market penetration. Specifically, sales promotion discounts incurred this quarter are the result of a promotion campaign to expand AMDL's sales footprint for newly released formulation of our Goodnak anti-aging line -- AMDL's highest profit margin product line. This is an investment and important part of our marketing strategy to increase sales revenue; bolster AMDL's competitive position in China and new markets and to drive long-term growth for the Company & our shareholders."

AMDL will discuss its business outlook during its regular quarterly conference call which is scheduled for the end of November. Specific details will be announced later this month.

Mr. MacLellan continued, "With the recent adjustments made in our business -- including an expanded and strengthened senior management team and board of directors, revised business strategy, and prioritized focus on securing additional capital to support AMDL's future growth -- we have embarked on the most exciting era in the Company's history. What lies ahead is the perfect opportunity to establish AMDL as a market-winning leader that delivers lucrative, long-term returns for our employees, partners, customers and shareholders."

Mr. MacLellan will cover today's news in a scheduled presentation he will deliver at Rodman & Renshaw's Annual Global Investment Conference taking place today, November 12th, 2008 at the New York Palace Hotel in New York City. Additionally, interested parties can download a copy of Mr. MacLellan's presentation through the AMDL corporate website located http://www.amdl.com under the "news" section. For additional information please contact Kristine Szarkowitz, SVP, AMDL Investor Relations at 206-310-5323 or kszarkowitz@amdl.com.

About AMDL:

Headquartered in Tustin, CA with operations in Shenzhen, Jiangxi, and Jilin, China, AMDL, Inc., along with its subsidiary Jade Pharmaceutical Inc. (JPI), is a vertically integrated bio-pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products. The company employs over 490 people in the U.S. and China.

Forward Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to AMDL Inc., except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties related to the Company's access to additional capital, competition and dependence on key management.

AMDL Contact:

Kristine Szarkowitz

Director-Investor Relations

kszarkowitz@amdl.com

(Tel:) 206. 310.5323


'/>"/>
SOURCE AMDL, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Metabolex Announces Positive Results From Phase 1a Clinical Trial of MBX-2982
2. Standard & Poors Announces Changes to U.S. Indices
3. Quanterix Corporation Announces the Addition of Dr. Robert Corn to its Scientific Advisory Board
4. Cardiums InnerCool Announces New Tissue-Specific UroCool(TM) System for Use in Prostate Surgeries
5. Tianyin Pharmaceutical Co., Inc. Announces First Quarter 2009 Financial Results
6. China Biologic Products Announces Third Quarter 2008 Results Conference Call
7. Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA Meeting
8. Heritage Labs Announces A1c Test Certification Milestone
9. Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights
10. The Binding Site Announces Trading Update for Year Ended September 30th 2008
11. CorMatrix Announces Pre-Clinical Data Suggesting Next Generation ECM Technology(TM) Can Improve Cardiac Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... -- Global demand for enzymes is forecast to grow ... billion.  This market includes enzymes used in industrial ... animal feed, and other markets) and specialty applications ... beverages will remain the largest market for enzymes, ... containing enzymes in developing regions.  These and other ...
(Date:6/27/2016)... Raleigh, NC (PRWEB) , ... June 27, 2016 ... ... a mission to bring innovative medical technologies, services and solutions to the healthcare ... development and implementation of various distribution, manufacturing, sales and marketing strategies that are ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
Breaking Biology Technology:
(Date:6/3/2016)... 2016 Das DOTM ... Nepal hat ein 44 Millionen ... Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an ... und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale ... teilgenommen, aber Decatur wurde als konformste und ...
(Date:5/24/2016)... 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology to ... display is the latest premium product recently added to the range of products distributed ... ... ... Imaging- LCD Medical Display- Ampronix News ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a provider ... MegaMatcher Automated Biometric Identification System (ABIS) , ... multi-biometric projects. MegaMatcher ABIS can process multiple complex ... any combination of fingerprint, face or iris biometrics. ... SDK and MegaMatcher Accelerator , which ...
Breaking Biology News(10 mins):